Palvella Therapeutics

Historical price data

Palvella Therapeutics is a public, clinical-stage biotech company with a mission to develop and commercialize novel therapies for rare genetic dermatological conditions with profound unmet medical need. Its core achievement is the development of the QTORIN™ drug delivery platform and its lead candidate, QTORIN rapamycin gel, which has reported positive Phase 3 data for the treatment of pachyonychia congenita (PC). The company's strategy is to leverage its proprietary formulation to achieve deep tissue penetration of rapamycin, targeting the root mTOR-driven pathology in specific keratin disorders, thereby pursuing rapid regulatory pathways and establishing a durable franchise in orphan dermatology.

QTORIN™ is a proprietary anhydrous gel formulation platform engineered to optimize the topical delivery of rapamycin (sirolimus) into the skin, enabling targeted inhibition of the mTOR pathway in epidermal and follicular tissues for the treatment of rare keratin disorders.

In its lead indication (PC), Palvella faces minimal direct competition with no approved therapies, relying on palliative care. Broader competition exists in pipeline indications (e.g., lasers for port-wine stains), but QTORIN rapamycin gel could be first-to-market with a standardized, FDA-approved topical formulation for several conditions.